首页 Biocept(usBIOC)-基本信息

Biocept(usBIOC)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

英文名称:Biocept


行业:医疗


简介:Biocept, Inc.于1997年5月12日成立于加利福尼亚


电话:1-858-3208200


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2017-05-30 Arnold Lyle J Officer Buy 25000 --
2017-05-30 Kennedy (Timothy C) Officer Buy 25000 --
2017-05-30 Singh (Veena) Officer Buy 25000 --
2017-05-30 Nall Michael W Chief Executive Officer Buy 50000 --
2017-01-18 Ally Bridge LB Healthcare Master Beneficial Owner of More than 10% Class Sell 254893 1.10
2017-01-17 Ally Bridge LB Healthcare Master Beneficial Owner of More than 10% Class Sell 549708 1.10
2017-01-16 Ally Bridge LB Healthcare Master Beneficial Owner of More than 10% Class Sell 876399 1.10
2016-10-18 Kennedy (Timothy C) Chief Financial Officer Buy 36363 --
2016-10-18 Nall Michael W Chief Executive Officer Buy 36363 --
2016-10-18 Neff (Edward A) Director Buy 227272 --
2016-10-18 Reiss (Claire K T) Beneficial Owner of More than 10% Class Buy 227272 --
2016-10-18 Singh (Veena) Officer Buy 10000 --
2016-10-18 Huebner (Bruce A) Director Buy 20000 --
2016-10-18 Wilson (Margaret Faye) Director Buy 13636 --
2016-10-18 Gerhardt (Bruce E) Director Buy 50000 1.10
2016-10-18 Hale (David F) Director Buy 90909 --
2016-10-18 Chandler (Marsha A) Director Buy 4545 1.10
2016-10-18 Arnold Lyle J Officer Buy 45000 --
2016-07-28 Kennedy (Timothy C) Chief Financial Officer Buy 75000 --
2016-07-05 Nall Michael W Chief Executive Officer Buy 75000 --
2016-07-05 Singh (Veena) Officer Buy 50000 --
2016-07-05 Arnold Lyle J Officer Buy 50000 --
2016-06-15 Hale (David F) Director Gift 13334 --
2016-06-15 Hale (David F) Director Gift 13334 --
2016-05-03 Neff (Edward A) Director Buy 100000 1.00
2016-05-03 Reiss (Claire K T) Beneficial Owner of More than 10% Class Buy 614273 1.00
2016-05-03 Hale (David F) Director Buy 50000 1.00
2016-05-03 Gerhardt (Bruce E) Director Buy 25000 1.00
2016-03-08 Nall Michael W Chief Executive Officer Gift 4450 --
2016-03-08 Nall Michael W Chief Executive Officer Gift 4450 --
第 页, 共 2 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Esfera Capital Gesti¨?n SGIIC 8000 0.04% 8000 -- 2019-07-31
Susquehanna International Group, LLP 27792 0.15% 27792 -- 2019-03-31
BARCLAYS CAPITAL Inc 30000 0.16% 30000 -- 2019-03-31
Barclays PLC 30150 0.16% 30150 -- 2019-03-31
Royal Bank of Canada 35053 0.19% -- -- 2019-03-31
Dimensional Fund Advisors, Inc. 63476 0.34% -47024 -42.56% 2019-03-31
Fidelity Management & Research Company 69670 0.37% -- -- 2019-07-31
Geode Capital Management, LLC 70353 0.37% 70353 -- 2019-03-31
Vanguard Group Inc 75207 0.40% 61296 440.63% 2019-03-31
Susquehanna Financial Group, LLLP 27792 0.15% 27792 -- 2019-03-31
TWO SIGMA SECURITIES, LLC 27476 0.15% 9447 52.40% 2019-03-31
BlackRock Inc 26479 0.14% 1 -- 2019-03-31
Virtu Financial LLC 15013 0.08% 15013 -- 2019-03-31
Ameriprise Financial Services Inc 20000 0.11% 20000 -- 2019-03-31
BMO Asset Management Inc 20000 0.11% 20000 -- 2019-03-31
Bank of Montreal 20000 0.11% 20000 -- 2019-03-31
Ameriprise Financial Inc 20000 0.11% 20000 -- 2019-03-31
Northern Trust Investments N A 21739 0.12% 21739 -- 2019-03-31
Northern Trust Corp 21739 0.12% 21739 -- 2019-03-31
Northern Trust Investments Inc 21775 0.12% 3 0.01% 2019-07-31
UBS Group AG 4370 0.02% 4370 -- 2019-03-31
Sabby Management LLC 57505 0.30% -84912 -59.62% 2018-12-31
JANE STREET GROUP, LLC 13165 0.07% 13165 -- 2018-12-31
Macquarie Funds Management HK Ltd. 8400 0.04% 8400 -- 2018-12-31
BlackRock Fund Advisors 67447 0.02% -- -- 2019-05-31
Morgan Stanley - Brokerage Accounts 4007 0.02% 4007 -- 2018-12-31
BlackRock Asset Management Canada Ltd 7574 0.04% 3786 99.95% 2019-05-31
Dimensional Fund Advisors LP 63476 0.34% -28024 -30.63% 2019-05-31
US Bancorp 826 0.01% -- -- 2018-12-31
FAF Advisors Inc 826 0.01% -- -- 2018-12-31
Mellon Investments Corporation 1552 0.01% 352 29.33% 2019-04-30
State Street Global Advisors 333 -- -- -- 2019-04-30
BlackRock 3237 0.02% 15 0.47% 2019-04-30
Macquarie Group Ltd 8400 0.14% 8400 -- 2018-12-31
Renaissance Technologies Corp 44240 0.76% 44240 -- 2018-12-31
Deutsche Bank AG 101 -- 101 -- 2018-09-30
BlackRock Advisors (UK) Ltd 100 -- 100 -- 2018-12-31
Pnc Bank, National Association 82 -- -- -- 2018-12-31
PNC Financial Services Group Inc 82 -- -- -- 2018-12-31
Group One Trading, LP 496 0.01% 496 -- 2018-09-30
Intellectus Partners, LLC 79 -- 1 1.28% 2018-09-30
Bank of America Corporation 32 -- 8 33.33% 2018-12-31
Garrison Bradford & Associates Inc -- -- -520 -100.00% 2018-09-30
Advisory Services Network, LLC 12 -- 12 -- 2018-09-30
Invesco Capital Management LLC 740 0.02% -- -- 2019-01-31
Vanguard Investments Australia Ltd 12324 0.30% 5 0.04% 2018-12-31
Vanguard 4034 0.10% 1 0.02% 2018-11-30
FMG LLC 12698 0.31% -- -- 2018-11-30
BlackRock Institutional Trust Company NA 737574 18.16% 75667 11.43% 2018-06-30
UBS Securities LLC 39076 0.96% -55861 -58.84% 2018-06-30
Bank of New York Mellon Corp 35979 0.89% -38196 -51.49% 2018-06-30
BNY Mellon Investment Management 35979 0.89% -- -- 2018-06-30
Raymond James & Associates 25000 0.62% -- -- 2018-06-30
BNY Mellon Asset Management North America Corporation 11580 0.29% 11580 -- 2018-11-30
Citadel Advisors Llc 70011 1.72% 70011 -- 2018-03-31
Creative Planning Inc 526829 12.97% 6686 1.29% 2018-06-30
Guggenheim Funds Investment Advisors LLC 596 0.02% -- -- 2018-09-14
Mellon Capital Management Corporation 35979 0.05% -- -- 2018-06-30
Cetera Advisors LLC 15000 0.02% 4250 39.53% 2018-03-31
State Street Corp 10000 0.01% -- -- 2018-03-31
Macquarie Investment Management Limited 11900 0.03% 11900 -- 2017-12-31
Morgan Stanley Smith Barney LLC 10000 0.03% -334 -3.23% 2017-09-30
Millennium Management LLC 22656 0.08% 22656 -- 2017-09-30
KCG AMERICAS LLC 17372 0.06% 17372 -- 2017-06-30
Metlife Securities Inc 166 -- -1 -0.60% 2016-09-30
Ladenburg Thalmann Asset Management Inc 925 0.01% -1 -0.11% 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BNYM Mellon SL Mkt Completion Fd -- -- -352 -100.00% 2019-06-30
NT Extended Equity Market Idx Fund - NL 50 -- -- -- 2019-06-30
State Street U.S. Extended Market Index 333 -- -- -- 2019-06-30
Fidelity 1613 0.01% -- -- 2019-06-30
iShares Core S&P Total US Stock Mkt ETF 1893 0.01% -- -- 2019-07-30
BlackRock Extended Equity Market 3233 0.02% -4 -0.12% 2019-06-30
Esfera III Titan Dynamic FI 8000 0.04% 8000 -- 2019-05-31
NT Ext Equity Market Index Fund - L 21657 0.11% -- -- 2019-06-30
Vanguard Extended Market Index Fund 155963 0.83% 3221 2.11% 2019-06-30
NT Ext Equity Mkt Fd - DC - NL 36 -- 3 9.09% 2019-06-30
iShares Core S&P US Total Market ETF 35 -- -1 -2.78% 2019-07-30
BNYM Mellon NSL Mkt Completion Fd Instl -- -- -1200 -100.00% 2019-06-30
Vanguard Total Stock Market Index Fund -- -- -4527 -100.00% 2018-10-31
DFA US Small Cap Portfolio -- -- -63476 -100.00% 2019-04-30
iShares Core MSCI AllCntry Wld exCan ETF 1 -- -- -- 2019-07-30
iShares Core S&P US Total Mkt ETF CADH 2 -- -1 -33.33% 2019-07-22
iShares Core Balanced ETF Portfolio 3 -- -- -- 2019-07-30
iShares Core Growth ETF Portfolio 5 -- -- -- 2019-07-30
NT US Market Cap Index Fund - Lending 32 -- -- -- 2019-06-30
NT Ext Equity Mkt Idx Fd - DC - NL 36 -- 3 9.09% 2019-06-30
Invesco Wilshire Micro-Cap ETF -- -- -740 -100.00% 2019-02-22
DFA US Targeted Value Portfolio -- -- -44200 -100.00% 2019-03-31
DFA Tax Managed US Small Cap Portfolio -- -- -3100 -100.00% 2018-09-30
Vanguard Balanced Index Fund -- -- -1493 -100.00% 2018-10-31
Vanguard Instl Total Stock Market Idx Fd -- -- -1 -100.00% 2018-10-31
BNYM Mellon NSL Market Completion Fund 1200 0.01% 1200 -- 2019-03-31
BNYM Mellon SL Market Completion Fund 352 -- -848 -70.67% 2019-03-31
1290 VT Micro Cap Portfolio -- -- -12698 -100.00% 2018-06-30
BNY Mellon Market Completion Fund -- -- -386 -100.00% 2018-12-31
iShares Micro-Cap ETF 65554 0.04% -- -- 2018-06-21
The Vanguard Total Stock Market Index 4034 0.10% 1 0.02% 2017-12-31
Vanguard Total Stock Mkt Idx 24638 0.54% 12320 100.02% 2018-07-31
DFA US Small Cap I 7981 0.35% 7981 -- 2018-07-31
Vanguard Balanced Index Inv 4063 0.18% -- -- 2018-07-31
DFA Tax-Managed US Small Cap 3100 0.14% 3100 -- 2018-07-31
Fidelity Spartan 2199 0.10% -- -- 2018-07-31
DFA US Targeted Value I 1667 0.07% 1667 -- 2018-07-31
Vanguard Extended Market Idx Inv 27828 0.61% 13915 100.01% 2018-07-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 313 0.01% 1 0.32% 2018-07-31
iShares Core S&P Total US Stock Mkt 1891 0.08% -- -- 2018-09-12
Wilshire Micro-Cap ETF 596 0.02% -- -- 2018-09-14
BNY Mellon EB DL Mkt Completion 35979 0.05% -- -- 2018-06-30
BlackRock Extended Equity Market K 96293 0.14% 2618 2.79% 2018-06-30
BNY Mellon Market Completion Fund UC1 11580 0.02% 11580 -- 2018-03-31
AXA/Lord Abbett Micro Cap K 12698 0.02% -- -- 2018-04-30
SSgA U.S. Total Market Index Fd Class I 2790 0.01% -182 -6.12% 2017-12-31
iShares Micro-Cap 65554 0.10% -- -- 2018-06-21
Fidelity Spartan® Total Market Idx Fund 21277 0.10% -- -- 2015-09-30
BlackRock Extended Equity Market Fund 17844 0.10% 17844 -- 2015-09-30
The Vanguard - Total Stk Mkt Idx Trust. CF 16900 0.10% -7700 -31.30% 2015-10-31
Vanguard Instl Total Stock Market Index 8600 -- -- -- 2015-10-31
Mellon Capital EB DL Mkt Completion Fund 5154 -- -- -- 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 60358 0.30% -- -- 2015-09-30
AXA/Lord Abbett Micro Cap Portfolio 2668 -- -- -- 2015-09-30

Ivor Royston Ivor Royston is an entrepreneur and businessperson who founded Hybritech, Inc., Forward Ventures Services LLC, IDEC Pharmaceuticals Corp. and IDEC Corp. (United States) and who has been at the helm of 5 different companies. Dr. Royston occupies the position of Chief Executive Officer & Director at Viracta Therapeutics, Inc. Dr. Royston is also on the board of Viropro, Inc., Biocept, Inc. and CONNECT. He previously held the position of Managing Member at Forward Ventures Services LLC, Chairman at TargeGen, Inc., Director at Morphotek, Inc., President & Chief Executive Officer of Sidney Kimmel Cancer Center, Chairman for LigoCyte Pharmaceuticals, Inc. and Member of the University of California San Diego. Ivor Royston received an undergraduate degree and a doctorate from The Johns Hopkins University.
David F. Hale Mr. David F. Hale is a Chairman at Adigica Health, Inc., a Chairman at Recros Medica, Inc., an Executive Chairman at MDRejuvena, Inc., a Chairman at Agility Clinical, Inc., a Non-Executive Chairman at Biocept, Inc., a Chairman at Advantar Laboratories, Inc., a Chairman at Conatus Pharmaceuticals, Inc., a Chairman at Hale BioPharma Ventures LLC, an Advisor at Windamere Venture Partners LLC, a Chairman at Clarify Medical, Inc., a Chairman at Intrepid Therapeutics, Inc., a Chairman at Oncternal Therapeutics, Inc., a Chairman at Rady Children's Institute for Genomic Medicine, a Chairman at Rich Diagnostics, Inc., a Chairman at Ridge Diagnostics, Inc., an Executive Chairman at Neurana Pharmaceuticals, Inc. and a General Partner at Hale Trading Co. LP. He is on the Board of Directors at Neurelis, Inc., BIOCOM, Dermata Therapeutics LLC, Idun Pharmaceuticals, Inc., San Diego Regional Economic Development Corp., Rady Children's Hospital & Health Center of San Diego and The Salk Institute for Biological Studies.
Lyle J. Arnold Founder of Molecular Biosystems, Inc., Aegea Biotechnologies, Inc. and Oasis Biosciences, Inc., Lyle J. Arnold is an entrepreneur who presently holds the position of President, Chief Executive Officer & Director at Aegea Biotechnologies, Inc. Dr. Arnold is also Chief Scientific Officer & SVP-Research at Biocept, Inc. In the past he was President & Chief Scientific Officer at Oasis Biosciences, Inc., Member of UC San Diego Moores Cancer Center and Vice President-Research at Gen-Probe, Inc. Lyle J. Arnold received an undergraduate degree from the University of California, Los Angeles and a doctorate from the University of California San Diego.
Michael J. Terry Michael J. Terry is Senior Vice President-Commercial Operations at Biocept, Inc. In the past he was Chief Executive Officer for Ligand Diagnostics, Vice President-Business Development for TrovaGene, Inc., Executive Vice President-European Operations at Lumenis Ltd. and Executive Vice President-European Operations at Lumenis, Inc. (a subsidiary of Lumenis Ltd.), Senior Vice President-Sales & Marketing of Sequenom, Inc. and Vice President-Global Sales of Aspect Medical Systems, Inc. Michael J. Terry received an undergraduate degree from the University of Wisconsin and an undergraduate degree from California State University-Fullerton.
Margaret Faye Wilson Margaret Faye Wilson founded Wilson Boyles & Co. LLC. Ms. Wilson is Chief Executive Officer at this company. She is also on the board of The Salk Institute for Biological Studies, Biocept, Inc. and BioMed Realty LP. In her past career Ms. Wilson occupied the position of Chairman-Security Pacific Financial Services at Bank of America Corp., Managing Director-Finance at Security Pacific Hoare Govett Ltd., Managing Director-Leveraged Buyout Group at Security Pacific Merchant Bank, Director & Senior VP-Risk Management Group at The Home Depot, Inc. and Chairman & President for Security Pacific Capital Markets Group, Inc. She received an MBA and a graduate degree from the University of Southern California and an undergraduate degree from Duke University.
Edwin C. Hendrick Edwin C. Hendrick is Chief Commercial Officer & Senior Vice President at Biocept, Inc. Mr. Hendrick previously held the position of Chief Commercial Officer of GenomeDx Biosciences, Inc., Executive Vice President-Sales & Marketing at Akers Biosciences, Inc., Vice President-Sales of CorVel Corp., Vice President for Ventana Medical Systems, Inc., Principal at Abbott Diagnostics, Inc., Vice President-Sales & Marketing of Esoterix, Inc., Executive Vice President-Sales & Marketing at PLUS Diagnostics, Inc. and Vice President-Sales & Marketing at US Pathology Labs, Inc. He received an undergraduate degree from the University of Kentucky.
Bruce A. Huebner Bruce A. Huebner is a businessperson who has been the head of 5 different companies. Mr. Huebner is on the board of Biocept, Inc. and Pasadena Bioscience Collaborative. In the past he held the position of Chairman of Vermillion, Inc., President & Chief Operating Officer for Ngen, Inc., President & Chief Executive Officer for TrovaGene, Inc., Managing Director at LynxCom Partners LLC, President at Osmetech Molecular Diagnostics, President at Osmetech, Inc. and Chief Operating Officer & Executive Vice President of Gen-Probe, Inc. Bruce A. Huebner received an undergraduate degree from the University of Wisconsin La Crosse.
Cory Dunn Cory Dunn is Vice President-Marketing at Biocept, Inc. In her past career she held the position of Project Manager at MiresBall, Assistant Director-Corporate Communications at Ionis Pharmaceuticals, Inc., Director-Marketing & Corporate Relations at BIOCOM, Consultant at Invitrogen Corp., Consultant at Upstate Group LLC and Consultant at The Salk Institute for Biological Studies. Ms. Dunn received a graduate degree from Stanford University and a graduate degree and an undergraduate degree from the University of California San Diego.
Bruce E. Gerhardt Bruce E. Gerhardt is on the board of Biocept, Inc. and Member of The American Institute of Certified Public Accountants. Mr. Gerhardt previously was Senior Accountant at KPMG (Auckland). He received an undergraduate degree from the University of Southern California.
Scott Nicholson Currently, Scott Nicholson holds the position of Vice President-Sales of Biocept, Inc. In the past he occupied the position of Principal at Oncotech, Inc. and Senior Vice President-Sales for PLUS Diagnostics, Inc. Mr. Nicholson received an undergraduate degree from Georgia State University.
Bruce E. Gerhardt Bruce E. Gerhardt is on the board of Biocept, Inc. and Member of The American Institute of Certified Public Accountants. Mr. Gerhardt previously was Senior Accountant at KPMG (Auckland). He received an undergraduate degree from the University of Southern California.
Michael W. Brown Michael W. Brown holds the position of General Counsel, Compliance & Privacy Officer at Biocept, Inc. In his past career he held the position of Principal at Edwards Lifesciences LLC, Chief Compliance Officer, VP & General Counsel at Clarient, Inc., Vice President for InSight Health Services Corp. and Corporate Counsel at Apria Healthcare, Inc. Michael W. Brown received an undergraduate degree from California State University-Fullerton and a graduate degree from Pepperdine University School of Law.
Michael W. Nall Michael W. Nall holds the position of President, Chief Executive Officer & Director at Biocept, Inc. In the past he held the position of Principal at Horizon Medical, Inc., Principal at IMPATH, Inc., General Manager-North American Sales & Marketing at Clarient Diagnostic Services, Inc. and General Manager-Sales & Marketing at Clarient, Inc. Michael W. Nall received an undergraduate degree from the University of Central Missouri.
Timothy C. Kennedy Timothy C. Kennedy is CFO, Senior VP-Operations & Secretary at Biocept, Inc. Mr. Kennedy is also on the board of MyCircle Health. In the past Mr. Kennedy was Vice President-Finance & Controller at Laboratory Corp. of America Holdings and Head-Finance for National Health Laboratories, Inc. (a subsidiary of Laboratory Corp. of America Holdings), Chief Financial Officer & General Manager at PLUS Diagnostics, Inc. and Chief Financial Officer for Millennium Health LLC. Mr. Kennedy received an undergraduate degree from Kean University.
Michael W. Nall Michael W. Nall holds the position of President, Chief Executive Officer & Director at Biocept, Inc. In the past he held the position of Principal at Horizon Medical, Inc., Principal at IMPATH, Inc., General Manager-North American Sales & Marketing at Clarient Diagnostic Services, Inc. and General Manager-Sales & Marketing at Clarient, Inc. Michael W. Nall received an undergraduate degree from the University of Central Missouri.
Marsha Alpert Chandler Marsha Alpert Chandler is on the board of Biocept, Inc. In her past career Dr. Chandler occupied the position of Chief Operating Officer & Executive Vice President for The Salk Institute for Biological Studies and Senior Vice Chancellor-Academic Affairs at the University of California San Diego. Dr. Chandler received a doctorate from the University of North Carolina at Chapel Hill.
Timothy C. Kennedy Timothy C. Kennedy is CFO, Senior VP-Operations & Secretary at Biocept, Inc. Mr. Kennedy is also on the board of MyCircle Health. In the past Mr. Kennedy was Vice President-Finance & Controller at Laboratory Corp. of America Holdings and Head-Finance for National Health Laboratories, Inc. (a subsidiary of Laboratory Corp. of America Holdings), Chief Financial Officer & General Manager at PLUS Diagnostics, Inc. and Chief Financial Officer for Millennium Health LLC. Mr. Kennedy received an undergraduate degree from Kean University.
Timothy C. Kennedy Timothy C. Kennedy is CFO, Senior VP-Operations & Secretary at Biocept, Inc. Mr. Kennedy is also on the board of MyCircle Health. In the past Mr. Kennedy was Vice President-Finance & Controller at Laboratory Corp. of America Holdings and Head-Finance for National Health Laboratories, Inc. (a subsidiary of Laboratory Corp. of America Holdings), Chief Financial Officer & General Manager at PLUS Diagnostics, Inc. and Chief Financial Officer for Millennium Health LLC. Mr. Kennedy received an undergraduate degree from Kean University.
Cecile Rose Vibat Cecile Rose Vibat occupies the position of Senior Director-Clinical & Translational Affairs at Biocept, Inc.
Pavel Tsinberg Currently, Pavel Tsinberg is Director-Technology Development at Biocept, Inc.

量化对比

全部评论 1

  • 【上海医药:子公司与BIOCAD HK正式签署协议 将新设合资公司】上海医药早间公告,全资子公司SPH PB与BIOCAD HK正式签署合资协议,将合资新设合资公司,注册资本金4亿美元。SPH PB 以现金出资2亿美元,占合资公司50.1%股权;BIOCAD HK以现金2994万美元及6个合作产品在中国大陆、香港特别行政区、澳门特别行政区和台湾的永久、独家的研发、生产、销售及其他商业化权利,共计出资1.996亿美元,占合资公司49.9%股权。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐